Can Wegovy cause an increased heart rate?

What the STEP trials recorded about heart rate

The most thorough data we have come from the STEP programme, the phase-3 trials that formed the basis for Wegovy's UK licence. In the STEP 1 trial published in the New England Journal of Medicine, researchers monitored cardiovascular parameters closely across 68 weeks in nearly 2,000 adults with obesity. A small but consistent rise in resting heart rate was recorded in the semaglutide group: on average around two to four beats per minute above baseline. That figure may sound modest, and for most healthy adults it is. Clinically, it sits below the threshold for concern on its own. The effect was more pronounced in the weeks following a dose step-up and appeared to level off once a maintenance dose was established. Importantly, the SELECT cardiovascular outcomes trial (which enrolled over 17,000 adults with obesity and established cardiovascular disease) found that semaglutide reduced major cardiovascular events overall, suggesting the heart-rate signal does not translate into increased cardiac risk for most patients. Context matters. A two-beat increase in someone with a resting pulse of 62 is very different from the same increase in someone already sitting at 95.

Why does Wegovy affect heart rate at all?

GLP-1 receptors are found not only in the gut and brain but in cardiac tissue and the sinoatrial node, the heart's natural pacemaker. Semaglutide's activation of these receptors appears to have a mild chronotropic effect, meaning it nudges the heart to beat a little faster. The precise mechanism is still being studied, but the leading explanation is a combination of direct receptor activity at the node and indirect effects from reduced vagal tone. This is not unique to semaglutide; similar observations have been made across the GLP-1 class. If you are curious about how the dose progression interacts with this, our dose-increase chart sets out the full titration schedule, which is relevant because the heart-rate change tracks most closely with dose steps. The effect is distinct from the palpitations some people notice in the first days after a new dose, those are more often linked to the nausea response and tend to resolve quickly as the body adjusts.

Who should be most alert to this side effect

For the majority of people prescribed Wegovy, a two-to-four beat rise in resting pulse is not clinically significant and they will not notice it day to day. The picture is different if you already have a fast resting heart rate, a known arrhythmia such as atrial fibrillation, or are taking medicines that also affect heart rhythm. In those situations the prescriber needs the full picture before treatment begins, and that assessment is exactly what the clinical consultation is for. A practical habit worth building in the first few months: check your resting heart rate each morning before getting out of bed, using a smartphone or a basic pulse oximeter. It takes under a minute and gives you a useful baseline to share with your clinical team if you have concerns. If your resting rate climbs above 100 beats per minute on repeated readings, or you notice palpitations that feel forceful, fluttering or irregular, contact a clinician. You can also explore more detail on heart-rate changes specifically linked to Wegovy and the distinction between expected and concerning patterns. The MHRA Yellow Card scheme allows patients to report any side effects they experience, including cardiovascular ones, and that reporting genuinely informs future safety guidance.

Managing concerns about heart rate alongside Wegovy treatment

There is no standard recommendation to stop Wegovy because of the modest heart-rate rise seen in trials, the prescriber's job is to weigh overall benefit against individual risk. What does matter is that your prescriber knows your cardiovascular baseline. If you have had a recent ECG, if you wear a heart-rate monitor, or if your GP has flagged anything about your resting pulse in the past, share that information at consultation. For people already on Wegovy who notice their pulse feels quicker than usual, our page on resting heart rate and semaglutide covers the distinction between expected pharmacological effect and signs that warrant prompt medical review. It is also worth knowing that dose matters: if you are still in the earlier stages of titration, the full licensed dose schedule explains the step-up intervals and why the prescriber controls the pace. The therapeutic dose of semaglutide is reached gradually for a reason, and much of the cardiovascular adjustment happens in those early weeks, a pattern you can read more about on our guide to Wegovy dose increases and what to expect at each stage. If you are thinking about whether Wegovy suits your health profile, or you want to understand how pricing compares across providers, our Wegovy cost guide is a useful starting point alongside the clinical side. And when you are ready to talk through your health history with a real clinician, starting a free consultation with our prescribers is straightforward, they review every application personally, the same day.